Home    Back

97. Ulcerative colitis
2,269 clinical trials,   1,331 drugs   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2014-001893-32-PL
(EUCTR)		20/01/201522/10/2014Placebo-controlled study to assess efficicay, safety and tolerability and to investigate the pharmacokinetics of GLPG1205 in subjects with moderate to severe Ulcerative ColitisPhase II, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients with Moderate to Severe Ulcerative Colitis Ulcerative Colitis
MedDRA version: 18.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Name: GLPG1205
Product Code: G321605
Other descriptive name: GLPG1205		Galapagos NVNULLNot RecruitingFemale: yes
Male: yes		60Phase 2Hungary;Czech Republic;Belgium;Poland;Russian Federation;Germany
2EUCTR2014-001893-32-CZ
(EUCTR)		19/01/201518/09/2014Placebo-controlled study to assess efficicay, safety and tolerability and to investigate the pharmacokinetics of GLPG1205 in subjects with moderate to severe Ulcerative ColitisPhase II, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients with Moderate to Severe Ulcerative Colitis Ulcerative Colitis
MedDRA version: 18.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Name: GLPG1205
Product Code: G321605
Other descriptive name: GLPG1205		Galapagos NVNULLNot RecruitingFemale: yes
Male: yes		60Phase 2Hungary;Czech Republic;Poland;Belgium;Russian Federation;Germany
3EUCTR2014-001893-32-DE
(EUCTR)		15/12/201424/09/2014Placebo-controlled study to assess efficacy, safety and tolerability and to investigate the pharmacokinetics of GLPG1205 in subjects with moderate to severe Ulcerative ColitisPhase II, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients with Moderate to Severe Ulcerative Colitis Ulcerative Colitis
MedDRA version: 18.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Name: GLPG1205
Product Code: G321605
Other descriptive name: GLPG1205		Galapagos NVNULLNot RecruitingFemale: yes
Male: yes		60Phase 2Hungary;Czech Republic;Poland;Belgium;Russian Federation;Germany
4EUCTR2014-001893-32-HU
(EUCTR)		08/12/201418/09/2014Placebo-controlled study to assess efficicay, safety and tolerability and to investigate the pharmacokinetics of GLPG1205 in subjects with moderate to severe Ulcerative ColitisPhase II, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients with Moderate to Severe Ulcerative Colitis Ulcerative Colitis
MedDRA version: 18.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Name: GLPG1205
Product Code: G321605
Other descriptive name: GLPG1205		Galapagos NVNULLNot RecruitingFemale: yes
Male: yes		60Phase 2Czech Republic;Hungary;Poland;Belgium;Russian Federation;Germany
5NCT02337608
(ClinicalTrials.gov)		December 20149/1/2015Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative ColitisPhase II, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients With Moderate to Severe Ulcerative ColitisUlcerative ColitisDrug: GLPG1205;Drug: PlaceboGalapagos NVNULLCompleted18 Years75 YearsBoth64Phase 2Belgium;Czech Republic;Germany;Hungary;Poland;Russian Federation
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2014-001893-32-BE
(EUCTR)		24/11/201418/09/2014Placebo-controlled study to assess efficicay, safety and tolerability and to investigate the pharmacokinetics of GLPG1205 in subjects with moderate to severe Ulcerative ColitisPhase II, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients with Moderate to Severe Ulcerative Colitis Ulcerative Colitis
MedDRA version: 17.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Name: GLPG1205
Product Code: G321605
Other descriptive name: GLPG1205		Galapagos NVNULLNot RecruitingFemale: yes
Male: yes		60Phase 2Hungary;Czech Republic;Poland;Belgium;Russian Federation;Germany

Back to top